illuminem logo
illuminem logo
  • Rankings
  • Use Cases
  • Pricing
  • Media
  • More
illuminem logo

About illuminem

AboutCareersBecome a Thought Leader

Advertising

Advertise with usPromote EventsOur Reach

Support

FAQsContact Us
Terms & Privacy Policy

© 2026 illuminem. All rights reserved. Various trademarks held by their owners.

  1. Home
  2. ›
  3. Industries
  4. ›
  5. health care
  6. ›
  7. Theravance biopharma
Company logo

Theravance biopharma | Sustainability Performance

https://www.theravance.com/

Develops and commercializes biopharmaceutical products, focusing on therapies for respiratory and other diseases. Engages in research, clinical trials, and regulatory submissions for new drug candidates.

2013

United States

51 - 200 employees

Biotechnology

$100M - 500M in revenue

$100M - 500M in profitability

Submit or report inaccurate dataDownload Company InsightsⓘBy downloading this report, you'll receive the most insightful and detailed analysis of the company's sustainability performance, compared to its peers. It includes key industry trends, carbon and energy intensity, nature impact, social metrics, and an in-depth look at key risks and controversies.

Sustainability Ranking & Industry Benchmark

#5979
Overallⓘ
#1323
in United Statesⓘ
#139
in Biotechnologyⓘ

Sustainability Maturity

ⓘ
​​0123456789​​%

Sustainability Intent

ⓘ

Available in
Scale package

Access
​​0123456789​​%

Industry Rank

148 out of 243

Overview
Financial Data
Business performanceCapital & innovationAnalyst projections

View similiar companies

Company logo
Biomarin Pharmaceutical

United States, Health Care, Biotechnology

Company logo
Exact Sciences

United States, Health Care, Biotechnology

Company logo
Krystal Biotech

United States, Health Care, Biotechnology

Market cap ⓘTotal market value of the company's outstanding shares, calculated by multiplying the share price by the number of shares outstanding.
792.0M$, 2026▼40.5% YoY
Revenue ⓘTotal revenue reported in the company's financial statements for the specified reporting year, reflecting income generated from primary business activities. Expressed in millions of USD.
64.0M$, 2024▼10.9% YoY
R&D intensity ⓘResearch and development expenditure expressed as a percentage of revenue, reflecting the company's relative investment in innovation.
57.81%2024

Controversy level

Very Low
Low
Noticeable
High
Severe
Download Controversy Analysis
Powered by illuminem

Reporting

sustainability report symbol

Sustainability Report

 Available
Not committed to key sustainability initiatives

Sustainability employees

ⓘWe follow the strictest rules to ensure compliance with all the relevant data protection laws, including GDPR. Click here for our Privacy Policy.

    Available in
    Scale package

    Access
  • Email
  • Email